PetVivo Names Gary DeMel, Executive Vice President Of Business Development
Minneapolis, Aug. 10, 2016 (GLOBE NEWSWIRE) -- For Immediate Release:
PetVivo Names Gary DeMel, Executive Vice President
of Business Development
MINNEAPOLIS, MN August 10, 2016 PetVivo Holdings, Inc. (OTCPINK:PETV) an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for pets is very pleased to announce that Gary DeMel has joined the company as Executive Vice President of Business Development. Mr. DeMel’s expansive background as an accomplished senior executive brings PetVivo more than thirty years of enterprise and emerging company experience.
Gary’s previous successes include his long-term employment and affiliation with Intel Corporation, where he held positions as Co-General Manager of the Enterprise Components Division and Senior Director of Worldwide Sales and Business Development.
Mr. DeMel’s impressive track record incorporates bringing advanced products to market in a manner that accomplishes global market dominance. His vision and market development strategies have helped build and drive some of the most successful sales, marketing, and business development teams in the world. His innovations in communications, video, network computing, and biotechnology products, have led the way for development of future generation technologies. Gary’s uncanny strength in evaluating new opportunities in vertical markets have driven the formation of key partnerships, created intellectual property, pioneered product development, and delivered valuable customer services. He has carried multiple companies through rapid and continuous revenue growth, increasing their corporate valuations as a result.
“We are extremely pleased to have Gary join our executive management team,” noted PetVivo’s CEO John Lai, “Gary brings a wealth of experience and business development expertise to our organization as we grow not only our veterinary business, but also our human clinical therapeutics in key markets around the globe.”
"I am very excited to become a member of PetVivo’s core management team during their break out year for commercializing their proprietary medical device products, said DeMel. "I'm looking forward to contributing to the Company’s growth strategies as we build a strong market position as an emerging growth biomedical device company."
PetVivo’s lead product, Kush Canine, a Veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is currently available for sale in limited quantities to key opinion leaders, with a targeted launch slated for later this year.
You can learn more about Kush Canine and PetVivo by visiting the company’s website at www.petvivo.com
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for commercial launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.
Forward-Looking Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
CONTACT:
John Lai
Chief Executive Officer
PetVivo Holdings, Inc.
Email: info@petvivo.com
Phone: 612-296-7305